|Mr. Yu Hong||Pres||157.95k||N/A||1973|
|Dr. William L. Fodor Ph.D.||Chief Scientific Officer||322.15k||N/A||1959|
|Mr. David Green||Interim CEO & Chairman||N/A||N/A||1964|
|Mr. Peter A. Pellegrino Jr.||Interim VP of Fin.||N/A||N/A||1975|
|Dr. Shunfu Hu Ph.D.||VP of Bus. Devel. & Operations||N/A||N/A||N/A|
Biostage, Inc., a biotechnology company, offers products to cure patients of cancers, injuries, and birth defects of the gastro-intestinal tract and the airways. The company is engaged in developing Biostage Esophageal Implant for the treating esophageal cancer. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2009 and is headquartered in Holliston, Massachusetts.
Biostage, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.